Core Viewpoint - In the first half of 2025, all 13 companies that submitted merger and acquisition projects for review in the A-share market were approved, resulting in a 100% approval rate [1]. Group 1: Independent Financial Advisors Performance Ranking - A total of 13 independent financial advisory firms participated in the 13 approved merger and acquisition projects [2]. - The top-ranked independent financial advisor was Dongfang Securities with 3 projects, followed by Huatai United Securities with 2 projects [3][4]. Group 2: Legal Advisors Performance Ranking - Ten law firms were involved in the legal services for the 13 approved merger and acquisition projects [5]. - The leading law firm was King & Wood Mallesons with 3 projects, while Guohao (Shanghai) and Shanghai Jintiancheng both ranked second with 2 projects each [6][7]. Group 3: Audit Firms Performance Ranking - Eleven accounting firms provided auditing services for the 13 approved merger and acquisition projects [8]. - The top audit firm was Tianjian with 3 projects, followed by Daxin and Xinyong Zhonghe, both with 2 projects [9]. Group 4: Asset Evaluation Firms Performance Ranking - Eleven asset evaluation firms were involved in the asset evaluation services for the 13 approved merger and acquisition projects [10]. - The leading asset evaluation firm was Jinzheng (Shanghai) with 3 projects, followed by Zhonglian Evaluation with 2 projects [11].

文/梧桐小新 7月7日，东海证券披露关于公司收到行政处罚事先告知书的公告，因在担任金洲慈航集团股份有限公司 2015年重大资产重组独立财务顾问的项目中，出具的相关文件存在重大遗漏、虚假记载，在独立财务顾问 业务中未勤勉尽责，包括：未为尚未完结的持续督导工作重新指定财务顾问主办人；未审慎核查其他中介 机构出具的专项报告；未保持职业怀疑，未对标的公司业绩承诺实现情况进行充分核查和验证。证监会拟 决定对东海证券责令改正，没收业务收入1500万元，并处以4500万元的罚款。 中国证监会认为，东海证券上述行为涉嫌违反了2005年修订的《中华人民共和国证券法》（以下简称2005 年《证券法》）第二十条第二款、第一百七十三条的规定，构成2005年《证券法》第二百二十三条的情 形。 依据2005年《证券法》第二百二十三条的规定， 中国证监会拟决定对东海证券责令改正，没收业务收入 1500万元，并处以4500万元的罚款。 根据相关规定，就中国证监会拟对东海证券实施的行政处罚，东海证券享有陈述、申辩并要求听证的权 利。 一、基本情况 涉嫌违法违规事项类别：重大资产重组项目未勤勉尽责。 二、主要内容 （一）涉嫌违法违规事实： 东海 ...

2025年5月16日，证监会资产重组新规落地 ，明确"允许未盈利硬科技资产注入上市公司"——这是继科 创板"科八条"、地方百亿并购基金后，政策层面对并购重组的又一次强力刺激。 回顾近年数据可以看出， 并购市场热度持续升温 ，企业关注度、参与度逐渐提高： " 1、并购重组市场形势 | 并购六条导向 | 行业 | 2024年平均并购金额(亿元) | 较近 10年均值增幅(%) | | --- | --- | --- | --- | | 向新质生产力转型升级 | 国防车工 | 575.75 | 495.02 | | | 轻工制造 | 133.51 | 420.03 | | | 传 娱 | 147.46 | 179.31 | | | 计算机 | 34.23 | 42.67 | | | 医药生物 | 33.62 | 40.48 | | | 汽车 | 34.48 | 21.02 | | 加强产业整合 | 非银金融 | 374.54 | 234.08 | | | 纺织服饰 | 73.73 | 113.98 | | | 商贸零售 | 101.25 | 111.79 | | | 父通运输 | 147.46 | 61.12 | ...

2025 年 7 月 8 日 银河观点集萃 责任编辑 周颖 ☎：010-80927635 网: zhouying_yj@chinastock.com.cn 分析师登记编码：S0130511090001 要闻 每日晨报 截至 2025 年 6 月末，我国外汇储备规模为 33174 亿美元 www.chinastock.com.cn 证券研究报告 请务必阅读正文最后的中国银河证券股份有限公司免责声明 固收:估值不低、结构性仍有空间,关注主线切换——7月转债策略展望。转 ● 债策略展望:保持仓位,关注行业景气扩散及政策拉动标的。综合考虑1)仓 位方面,尽管转债市场估值不便宜,但整体偏权市场尚未关注到风偏显著回落 的线索,因而建议稳健中性配置;2)基本面维度,偏好景气有改善的行业转 债标的,如有色、机械、农业、计算机等;3)主题维度,关注可能受益于政 治局会议政策拉动的消费、高新制造,供给侧改革推进电新、汽车等行业标的; 4）风险上,关注行业层面估值偏高对个券的扰动、可能受中美贸易政策变化 的标的。具体配置策略见正文。7月推荐转债组合包括国投转债、燃 23 转债、 青农转债、兴业转债、金铜转债、松原转债、安集转债、道 ...

公告还称，本次交易尚需中国证监会予以注册以及相关法律法规所要求的其他可能涉及的必要批准、核 准、备案或许可(如需)后方可正式实施，能否实施尚存在不确定性。 中国船舶集团旗下两大市值千亿元级上市公司重组整合迎来重要进展。7月4日，中国船舶工业股份有限 公司(以下简称"中国船舶")发布公告称，公司吸收合并中国船舶重工股份有限公司(以下简称"中国重工 （601989）")事项获上海证券交易所(以下简称"上交所")审核通过。 此次重组完成后，存续公司中国船舶将成为全球最大造船上市公司，资产规模、营业收入规模、手持订 单数均领跑全球。截至7月4日收盘，中国船舶市值达到1467亿元，中国重工市值为1056亿元。 上交所审议通过 7月4日，中国船舶发布公告称，中国船舶拟向中国重工全体换股股东发行A股股票的方式换股吸收合并 中国重工。上交所并购重组审核委员会7月4日召开2025年第8次并购重组审核委员会审议会议，对公司 本次交易的申请进行了审议。审议结果为，本次交易符合重组条件和信息披露要求。 此前，2024年9月2日晚，中国船舶发布关于筹划重大资产重组停牌公告。公告称，为进一步聚焦国家重 大战略和兴装强军主责主业、加快船舶 ...

Core Viewpoint - Chuangjian Medical (NQ873474) reported a significant decline in net profit for the fiscal year 2024, with a year-on-year decrease of 50.84% [1] Financial Performance - The company achieved operating revenue of 288.15 million yuan, a year-on-year increase of 1.82% [2] - The net profit attributable to shareholders was 33.82 million yuan, down 50.84% from the previous year [2] - The net profit after deducting non-recurring gains and losses was 26.77 million yuan, a decrease of 58.04% [2] - Basic earnings per share were 0.81 yuan, down 53.98% compared to 1.76 yuan in the previous year [2] - The weighted average return on equity was 6.31%, compared to 23.55% in the previous year [2] - The gross profit margin for the period was 73.94%, down from 78.17% year-on-year [2] Business Segments - Revenue from terminal products reached 182 million yuan, reflecting a year-on-year growth of 29.95%, although the gross margin decreased to 70.81% [3] - The revenue from the restructured collagen raw material business was 104 million yuan, down 26.23% year-on-year, with a gross margin of 79.24%, a decrease of 2.09% [3] - The decline in performance was attributed to strategic adjustments in product structure and a reduction in sales volume for certain products [3] Employee Statistics - The total number of employees increased to 503, up 18.35% from 425 at the end of the previous year [4]

创业板指盘初涨幅扩大至1%，上证指数现涨0.15%；大医药概念集体反弹，CRO、创新药、单抗、重组 蛋白等概念走强；全市约3800股上涨，1300股下跌，主力资金净流出超20亿元。 ...

Market Overview - The A-share market opened with mixed performance, with the Shanghai Composite Index up 0.04% at 3474.63 points, while the Shenzhen Component Index and the ChiNext Index fell by 0.04% and 0.03% respectively [2][3] - The Hong Kong market saw the Hang Seng Index rise by 0.17% and the Hang Seng Tech Index increase by 0.28%, with notable gains in companies like Far East Horizon and Kingstone Pharmaceuticals [4] Sector Performance - Advanced packaging, semiconductor, and power sectors showed strength, while tax refund stores, recombinant protein, and CPO concepts opened lower [1] - The storage chip sector led gains, with companies like Jingzhida rising over 7% following news of Changxin Memory's listing guidance [1] - Shipping and port concepts also performed well, with Ningbo Ocean and Ningbo Shipping both rising over 3% amid news of Houthi attacks on Red Sea merchant ships [1] Monetary Policy - The central bank conducted a 690 billion yuan reverse repurchase operation with a rate of 1.40%, while 1310 billion yuan of reverse repos are set to mature today [5] Currency Exchange - The RMB against the USD was adjusted down by 28 basis points to a midpoint of 7.1534, with the onshore closing price at 7.1747 [6]

Core Viewpoint - The life sciences upstream sector is showing signs of recovery with a year-on-year growth rate of 9.5% in Q1 2025, driven by stable investment and financing, cost reduction, and domestic substitution trends [1] Group 1: Industry Trends - The life sciences upstream sector, which includes instruments, consumables, raw materials, and services, is characterized by specialization, high barriers, and cyclicality [1] - The sector experienced a downturn after rapid growth during the pandemic, but leading companies are expanding and increasing their international presence [1] - Major companies are expected to see a revenue growth rate of 10.75% in 2024, with a significant recovery in Q1 2025 compared to 2023 [1] Group 2: Market Opportunities - The global and Chinese biopharmaceutical markets are thriving, with projections indicating that the Chinese antibody drug market will reach 510.8 billion RMB by 2030 and the CGT market will reach 2.59 billion USD by 2025, providing substantial market growth for the upstream sector [2] - The domestic innovative drug market is heating up, which is likely to accelerate demand for life sciences upstream products [2] Group 3: Domestic Substitution and Innovation - The increasing tariff barriers are enhancing domestic self-sufficiency, allowing local companies to enter major supply chains as cost reduction and supply chain security become more critical [2] - Long-term success in domestic substitution will depend on technological innovation, with local firms increasing R&D investments and moving from low-end to mid-to-high-end products [2] Group 4: Mergers and Acquisitions - Historical analysis of global life sciences giants shows that mergers and acquisitions have been key to their growth, allowing them to focus on core businesses and expand capabilities [3] - Recent favorable policies for mergers and acquisitions, along with the cash-rich status of many life sciences companies, are expected to accelerate consolidation in the sector [3] - Domestic companies are likely to replicate the growth paths of overseas giants through mergers and acquisitions, increasing industry concentration and extending their reach into downstream markets [3]

Core Viewpoint - Shaoyang Hydraulic (301079) has announced a major asset restructuring plan, revealing significant changes in shareholder composition and stock price movements prior to the announcement [1][19]. Shareholder Changes - A new investor named "Li Yuanfang" has emerged as the fifth largest shareholder, holding 724,200 shares, which is 0.66% of the total share capital. This investor was not listed in the previous quarterly report [1][4]. - Another shareholder, "Cao Kangseng," is now the seventh largest shareholder with 537,750 shares, representing 0.49% of the total share capital [3][5]. - Notably, foreign entities Morgan Stanley & Co. International PLC and UBS AG were absent from the latest shareholder list [3][5]. Stock Price Movements - On the trading day before the announcement, Shaoyang Hydraulic's stock price rose by 11.93%, closing at 31.90 CNY per share, compared to 28.50 CNY per share 21 trading days prior [9][19]. - The stock's performance was contrasted with the broader market, where the ChiNext Index fell by 1.74% and the CITIC Machinery Index dropped by 2.62% during the same period [9]. Financial Performance - Shaoyang Hydraulic reported a revenue of 276 million CNY in 2023, a decrease of 8.32% year-on-year, and a net profit of 6.58 million CNY, down 86.88% [16]. - For 2024, the company expects a revenue increase to 351 million CNY, a rise of 27.33%, but a slight decline in net profit to 6.40 million CNY, down 2.76% [16][18]. - The company ranks 142nd out of 213 in total market capitalization within its industry, indicating a relatively weak financial position compared to peers [18]. Asset Acquisition - The target company for the acquisition, Chongqing Xincheng Hangrui Technology Co., Ltd., reported revenues of 353.23 million CNY and 346.65 million CNY for 2023 and 2024, respectively, with net profits of 43.51 million CNY and 30.23 million CNY [14][15]. - The acquisition aims to create synergies and enhance the company's supply chain [14]. Confidentiality Measures - Shaoyang Hydraulic has stated that it has implemented necessary measures to prevent information leakage regarding the asset restructuring and has adhered to confidentiality obligations [10][19].